Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat

P. Kala, H. Bartušková, J. Piťha, Z. Vaňourková, S. Kikerlová, Š. Jíchová, V. Melenovský, L. Hošková, J. Veselka, E. Kompanowska-Jezierska, J. Sadowski, O. Gawrys, H. Maxová, L. Červenka

. 2020 ; 21 (24) : . [pub] 20201208

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21011753

Grant support
32218 Univerzita Karlova v Praze
NV 18-02-00053 Ministry of Health of the Czech Republic

Doxorubicin's (DOX) cardiotoxicity contributes to the development of chemotherapy-induced heart failure (HF) and new treatment strategies are in high demand. The aim of the present study was to characterize a DOX-induced model of HF in Ren-2 transgenic rats (TGR), those characterized by hypertension and hyperactivity of the renin-angiotensin-aldosterone system, and to compare the results with normotensive transgene-negative, Hannover Sprague-Dawley (HanSD) rats. DOX was administered for two weeks in a cumulative dose of 15 mg/kg. In HanSD rats DOX administration resulted in the development of an early phase of HF with the dominant symptom of bilateral cardiac atrophy demonstrable two weeks after the last DOX injection. In TGR, DOX caused substantial impairment of systolic function already at the end of the treatment, with further progression observed throughout the experiment. Additionally, two weeks after the termination of DOX treatment, TGR exhibited signs of HF characteristic for the transition stage between the compensated and decompensated phases of HF. In conclusion, we suggest that DOX-induced HF in TGR is a suitable model to study the pathophysiological aspects of chemotherapy-induced HF and to evaluate novel therapeutic strategies to combat this form of HF, which are urgently needed.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011753
003      
CZ-PrNML
005      
20220530151421.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms21249337 $2 doi
035    __
$a (PubMed)33302374
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kala, Petr $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $7 xx0273373
245    10
$a Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat / $c P. Kala, H. Bartušková, J. Piťha, Z. Vaňourková, S. Kikerlová, Š. Jíchová, V. Melenovský, L. Hošková, J. Veselka, E. Kompanowska-Jezierska, J. Sadowski, O. Gawrys, H. Maxová, L. Červenka
520    9_
$a Doxorubicin's (DOX) cardiotoxicity contributes to the development of chemotherapy-induced heart failure (HF) and new treatment strategies are in high demand. The aim of the present study was to characterize a DOX-induced model of HF in Ren-2 transgenic rats (TGR), those characterized by hypertension and hyperactivity of the renin-angiotensin-aldosterone system, and to compare the results with normotensive transgene-negative, Hannover Sprague-Dawley (HanSD) rats. DOX was administered for two weeks in a cumulative dose of 15 mg/kg. In HanSD rats DOX administration resulted in the development of an early phase of HF with the dominant symptom of bilateral cardiac atrophy demonstrable two weeks after the last DOX injection. In TGR, DOX caused substantial impairment of systolic function already at the end of the treatment, with further progression observed throughout the experiment. Additionally, two weeks after the termination of DOX treatment, TGR exhibited signs of HF characteristic for the transition stage between the compensated and decompensated phases of HF. In conclusion, we suggest that DOX-induced HF in TGR is a suitable model to study the pathophysiological aspects of chemotherapy-induced HF and to evaluate novel therapeutic strategies to combat this form of HF, which are urgently needed.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x toxicita $7 D000970
650    12
$a krevní tlak $7 D001794
650    _2
$a kardiotoxicita $7 D066126
650    _2
$a doxorubicin $x toxicita $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x etiologie $x metabolismus $x patofyziologie $7 D006333
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a renin $x genetika $7 D012083
650    12
$a renin-angiotensin systém $7 D012084
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bartušková, Hana $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Piťha, Jan $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Vaňourková, Zdenka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Kikerlová, Soňa $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Jíchová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Hošková, Lenka $u Department of Cardiology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Veselka, Josef $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
700    1_
$a Kompanowska-Jezierska, Elżbieta, $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 01-224 Warsaw, Poland $d 1959- $7 xx0273376
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 01-224 Warsaw, Poland
700    1_
$a Gawrys, Olga $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 01-224 Warsaw, Poland
700    1_
$a Maxová, Hana $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, 110 00 Prague, Czech Republic
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, 110 00 Prague, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 24 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33302374 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20220530151419 $b ABA008
999    __
$a ok $b bmc $g 1650199 $s 1132132
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 24 $e 20201208 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 32218 $p Univerzita Karlova v Praze
GRA    __
$a NV 18-02-00053 $p Ministry of Health of the Czech Republic
LZP    __
$a Pubmed-20210420
Back

Find record

Citation metrics

Archiving options